Leadership

No introduction necessary

Management Team

Roger Moody

Chief Executive Officer

Mr. Moody has more than 20 years of experience in leading emerging healthcare and technology companies from development stage through to global commercialization. Most recently, Mr. Moody served as Chief Finance Officer at Nanosphere, Inc. (Nasdaq:NSPH), a molecular diagnostics company, where he led the company's IPO and five follow-on public stock offerings and built the operational infrastructure to support its global growth plans.  Mr. Moody also spent six years at Medsn, a medical communications company where he served as Chief Operating Officer, Managing Director and formerly as Chief Finance Officer. Mr. Moody also served in various corporate development positions at Volpe Brown Whelan & Company, Genuity and IBM.  Mr. Moody holds a BS from Syracuse University and an MBA from the University of Chicago, Graduate School of Business.

 

Barry Crane

Chief Technical Officer

Mr. Crane has more than 25 years of experience in the medical device industry. He directed the trans-Atlantic R&D teams of scientists and engineers that were responsible for the development and launch, in 1995, of the first intravascular optical blood gas sensor at Pfizer/Biomedical Sensors. Prior to Biomedical Sensors, Mr. Crane worked for Smith & Nephew and Pfizer. Mr. Crane is one of the co-founders of SciSense, Ltd. (now GlySure Ltd.) and holds degrees in Chemistry and Microbiology.

 

Albert Leung

Chief Medical Officer

Dr. Leung has over 20 years of experience in healthcare companies and clinical endocrinology, with extensive experience in the design and execution of clinical trials, as well as interacting with regulatory agencies worldwide. Prior to joining GlySure, he was an independent clinical sciences consultant and provided strategic, clinical, operational and regulatory advice to companies of all sizes. Previously, he was an executive director at Merck & Co., Inc. (MSD), where he headed the Endocrine Clinical Research Section. He has led product development teams at Johnson & Johnson for diabetes and obesity and for novel drug delivery devices and formulations. Dr. Leung received his clinical training in diabetes and endocrinology at the Massachusetts General Hospital and holds MD and PhD degrees from the University of Iowa. He practised as a clinical endocrinologist prior to joining industry.

 

Sally Mahoney

Director of Finance and Corporate Services

Ms. Mahoney, FCCA has been a member of the Association of Certified Accountants since 2001. She has 25 years of finance experience working in several business sectors. Prior to joining GlySure, Ms. Mahoney worked for a professional body, as Director of Finance and Corporate Services and for a short period in the Charity sector. Ms. Mahoney returns to manufacturing having previously worked for 15 years at Pfizer/Biomedical Sensors, ultimately in the post of Financial Controller. 

 

Jan Walters

Director of Quality Assurance & Regulatory Affairs

Ms. Walters has over 20 years' experience in worldwide regulatory affairs and quality assurance in the medical device industry. Prior to joining GlySure she was V.P. QA/RA for Pfizer/Biomedical Sensors and worked directly with US, European, Canadian and Japanese regulatory agencies. At GlySure she is responsible for establishing and maintaining company-wide quality management systems and product registration. Ms. Walters has a Masters degree in History from Oxford Brookes University and is a member of the Institute for Quality Assurance.

 

Board of Directors

William Moffitt

Executive Chairman of the Board

William P. Moffitt has more than 35 years' experience in the medical technology industry. For the past 20 years he has focused on commercializing novel technologies that have helped to shape the healthcare industry. Mr. Moffitt was President and Chief Executive Officer of Nanosphere, Inc. ("NSPH"), a US-based nanotechnology life sciences company. Mr. Moffitt previously served as President and Chief Executive Officer of point-of-care diagnostics manufacturer i-STAT Corp., where he led the commercialization from its early stages through to its successful IPO in 1992 and its subsequent acquisition in 2003 by Abbott Laboratories. Mr. Moffitt is a director of two other private companies in the life sciences industry.

 

Roger Moody

Chief Executive Officer

Mr. Moody has more than 20 years of experience in leading emerging healthcare and technology companies from development stage through to global commercialization. Most recently, Mr. Moody served as Chief Finance Officer at Nanosphere, Inc. (Nasdaq:NSPH), a molecular diagnostics company, where he led the company's IPO and five follow-on public stock offerings and built the operational infrastructure to support its global growth plans.  Mr. Moody also spent six years at Medsn, a medical communications company where he served as Chief Operating Officer, Managing Director and formerly as Chief Finance Officer. Mr. Moody also served in various corporate development positions at Volpe Brown Whelan & Company, Genuity and IBM.  Mr. Moody holds a BS from Syracuse University and an MBA from the University of Chicago, Graduate School of Business.

 

Barry Crane

Chief Technical Officer

Mr. Crane has more than 25 years of experience in the medical device industry. He directed the trans-Atlantic R&D teams of scientists and engineers that were responsible for the development and launch, in 1995, of the first intravascular optical blood gas sensor at Pfizer/Biomedical Sensors. Prior to Biomedical Sensors, Mr. Crane worked for Smith & Nephew and Pfizer. Mr. Crane is one of the co-founders of SciSense, Ltd. (now GlySure Ltd.) and holds degrees in Chemistry and Microbiology.

 

Anne Glover

Amadeus Capital Partners

Ms. Glover is co-founder and Chief Executive of Amadeus Capital Partners Limited, a UK-based venture capital fund. At Amadeus, she has served on the board of several medical technology companies and guided their growth to successful exits. Her background in venture capital includes positions with Apax Partners & Company Ventures and later Calderstone Capital. Previously, she served as COO with the Virtuality Group and has worked with Cummins Engine and Bain & Co in Boston.  She currently serves on the boards of Covestor, Nomad and the Royal Society Enterprise Fund.  Ms. Glover is the past-Chairman of the BVCA association and has a degree in Management from Yale School of Management.

 

Frank Kenny

Delta Partners

Mr. Kenny founded Delta Partners in 1994, having previously worked in the VC industry with Burr, Egan, Deleage & Co. in Boston from 1983 to 1993. He was on the Board of many private technology companies in the U.S.A. and was on two NASDAQ Boards, Abacus Direct Corporation and Vivid Technologies Inc. from 1989 to 1999. Mr. Kenny currently serves on a number of private Boards, including Advanced Surgical Concepts, Qumas, and Neoss, and on the board of publicly quoted AGI Therapeutics plc. Mr. Kenny holds a B. Comm. and M. Econ. Sc. from University College Dublin and an MBA from University of Chicago.

 

Patrick Paul

Chester Investments

Mr. Paul has more than 25 years' experience in the medical device industry in North America and Europe. He is the founder and a principal of Chester Investments. In 1975, Mr. Paul co-founded Support Systems International, SA and later became its Chairman and Chief Executive Officer until its acquisition by Hillenbrand Industries, Inc. in 1985. An experienced investor in life sciences companies, he was a founding investor and Chairman of Tissue Science Laboratories plc (London, AIM) until its recent acquisition by Covidien, and is a Non-Executive Director of Optos plc (LON:OPTS). Mr. Paul has a degree in Engineering from the University of Southampton and is a Chartered Accountant.